Display options
Share it on

Pharmaceutics. 2020 Jan 02;12(1). doi: 10.3390/pharmaceutics12010035.

Spatial Distribution of (R)-salbutamol in Rat Brain Following Nasal and Intravenous Administration Using DESI-MS.

Pharmaceutics

Rui Zhang, Jie Wu, Siyu Liu, LiangJun Deng, Junhua Hu, Xi Chen, Wen Tan

Affiliations

  1. Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, Guangdong, China.
  2. School of Pharmacy, Jinan University, Guangzhou 510632, Guangdong, China.
  3. YZ Health-tech Inc., Hengqin District, Zhuhai 519000, Guangdong, China.
  4. Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Selangor Darul Ehsan, Malaysia.

PMID: 31906459 PMCID: PMC7023290 DOI: 10.3390/pharmaceutics12010035

Abstract

Recent studies have shown that β2-Adrenoreceptor is a regulator of the a-synuclein gene driving risk of Parkinson's disease. The β2-AR agonist (R)-salbutamol, eutomer of rac-salbutamol, may hold therapeutic potential for Parkinson's disease (PD) following nasal administration. In this study, we use desorption electrospray ionization mass spectrometry (DESI-MS) to analyze spatial distribution of (R)-salbutamol in rat brain following nasal and intravenous administration. Here, we report that (R)-salbutamol efficiently deliver to the brain and had more drug dosage exposure in rat's brain through nasal route administration than that of intravenous route administration. In conclusion, administering (R)-salbutamol through nasal route of administration may hold advantages in improving spatial distribution and increased exposure of drug in brain.

Keywords: Parkinson’s disease; desorption electrospray ionization; nasal administration; salbutamol; β2-adrenergic receptor

References

  1. Mov Disord. 2018 Sep;33(9):1465-1471 - PubMed
  2. Eur J Pharm Sci. 2000 Jul;11(1):1-18 - PubMed
  3. Eur J Pharm Sci. 2014 Aug 18;60:32-9 - PubMed
  4. Science. 2017 Sep 1;357(6354):891-898 - PubMed
  5. Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18120-5 - PubMed
  6. Am J Respir Cell Mol Biol. 2006 Jan;34(1):119-27 - PubMed
  7. Genome Med. 2017 Oct 19;9(1):88 - PubMed
  8. J Allergy Clin Immunol. 1999 Aug;104(2 Pt 2):S31-41 - PubMed
  9. Otolaryngol Head Neck Surg. 2010 Nov;143(5 Suppl 3):S3-8 - PubMed
  10. Pharm Res. 2000 Jun;17(6):737-42 - PubMed
  11. Braz J Med Biol Res. 2005 May;38(5):723-30 - PubMed
  12. Am J Physiol Lung Cell Mol Physiol. 2000 Oct;279(4):L675-82 - PubMed
  13. J Pharm Pharmacol. 1984 Mar;36(3):200-2 - PubMed
  14. Eur J Pharmacol. 1996 Jan 25;296(2):173-80 - PubMed
  15. Allergol Int. 2019 Jul;68(3):335-341 - PubMed
  16. J Drug Target. 2000;8(6):353-5 - PubMed
  17. Neuroscience. 2004;127(2):481-96 - PubMed
  18. Mol Pharmacol. 1998 Mar;53(3):347-54 - PubMed
  19. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Oct 1;1002:218-27 - PubMed
  20. J Sep Sci. 2019 Aug 7;: - PubMed
  21. Pulm Pharmacol Ther. 2013 Apr;26(2):239-48 - PubMed
  22. J Pharm Pharmacol. 2009 May;61(5):669-75 - PubMed
  23. Nat Rev Drug Discov. 2007 Aug;6(8):650-61 - PubMed
  24. J Pharm Pharmacol. 2004 Oct;56(10):1211-5 - PubMed

Publication Types

Grant support